Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 4
2022 2
2023 1
2024 6
2025 8
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Current and future immunotherapy for breast cancer.
Heater NK, Warrior S, Lu J. Heater NK, et al. J Hematol Oncol. 2024 Dec 25;17(1):131. doi: 10.1186/s13045-024-01649-z. J Hematol Oncol. 2024. PMID: 39722028 Free PMC article. Review.
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negati …
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrol …
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Bañuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P; ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators. Tolaney SM, et al. N Engl J Med. 2026 Jan 22;394(4):354-366. doi: 10.1056/NEJMoa2508959. N Engl J Med. 2026. PMID: 41564397 Clinical Trial.
BACKGROUND: Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or me …
BACKGROUND: Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet nee …
New Treatment Approaches for Triple-Negative Breast Cancer.
Riaz F, Gruber JJ, Telli ML. Riaz F, et al. Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e481154. doi: 10.1200/EDBK-25-481154. Epub 2025 Jun 3. Am Soc Clin Oncol Educ Book. 2025. PMID: 40460322 Free article. Review.
Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. ...Antibody-drug conjugates have been an important advance in the treatment of advanced TNBC, although these drugs do not represent a T …
Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. ...An …
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. Bardia A, et al. Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38686016 Free PMC article.
BACKGROUND: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients with residual invasive disease after neoadjuvant therapy have a high risk of disease recurrence and worse survival outcomes than those who have …
BACKGROUND: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients wit …
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab ( capecitabine) for residual triple-negative breast cancer.
Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. Tolaney SM, et al. Future Oncol. 2024;20(31):2343-2355. doi: 10.1080/14796694.2024.2357534. Epub 2024 Jun 26. Future Oncol. 2024. PMID: 38922307 Free PMC article.
Patients with early-stage triple-negative breast cancer (TNBC) with residual invasive disease after neoadjuvant therapy have a high risk of recurrence even with neoadjuvant and adjuvant treatment with pembrolizumab. Sacituzumab …
Patients with early-stage triple-negative breast cancer (TNBC) with residual invasive disease after neoad …
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.
Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, Graff SL, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G. Schmid P, et al. Ther Adv Med Oncol. 2025 Apr 17;17:17588359251327992. doi: 10.1177/17588359251327992. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40297626 Free PMC article.
BACKGROUND: Standard of care (SoC) for patients with advanced triple-negative breast cancer (TNBC) whose tumors express PD-L1 (combined positive score 10) is chemotherapy plus anti-PD-(L)1 inhibitors; however, prognosis and survival for most p …
BACKGROUND: Standard of care (SoC) for patients with advanced triple-negative breast cancer (TNBC) whose …
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.
McArthur HL, Tolaney SM, Dent R, Schmid P, Asselah J, Liu Q, Meisel JL, Niikura N, Park YH, Werutsky G, Bianchini G, Andersen JC, Kozarski R, Rokutanda N, Pistilli B, Loibl S. McArthur HL, et al. Ther Adv Med Oncol. 2025 Feb 5;17:17588359251316176. doi: 10.1177/17588359251316176. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 39917260 Free PMC article.
BACKGROUND: Despite treatment advances for patients with early-stage triple-negative breast cancer (TNBC) and hormone receptor (HR)-low/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, treatments that improve clinical out …
BACKGROUND: Despite treatment advances for patients with early-stage triple-negative breast cancer (TNBC) …
Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review.
Hammershøi Madsen AM, Løvendahl Eefsen RH, Nielsen D, Kümler I. Hammershøi Madsen AM, et al. Breast J. 2024 Jul 11;2024:9083055. doi: 10.1155/2024/9083055. eCollection 2024. Breast J. 2024. PMID: 39742383 Free PMC article.
INTRODUCTION: Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence of estrogen and the human epidermal 2 receptor and also a lack of targeted therapy options. ...CONCLUSION: In most of the studies incl …
INTRODUCTION: Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the ab …
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D. Schettini F, et al. Cancer Treat Rev. 2022 Dec;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub 2022 Sep 28. Cancer Treat Rev. 2022. PMID: 36202026 Free article.
Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. ...Trastuzumab deruxtecan in HER2-low mTNBC performed similarly and was the best advanced-line treatment in term …
Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncert …
Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
Cipriano É, Mesquita A. Cipriano É, et al. Breast Cancer (Auckl). 2021 Mar 22;15:11782234211002491. doi: 10.1177/11782234211002491. eCollection 2021. Breast Cancer (Auckl). 2021. PMID: 33814914 Free PMC article. Review.
Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and currently with few treatment options. ...Some targeted drugs were recently approved for these patients: two poly(ADP-ribose) polymerase inhibito …
Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and curr …
22 results